Foghorn Therapeutics (FHTX) Assets Average (2020 - 2026)

Foghorn Therapeutics' Assets Average history runs 7 years deep, the most recent figure standing at $210.1 million for Q1 2026.

• In Q1 2026, Assets Average fell 22.56% year-over-year to $210.1 million; the TTM figure through Mar 2026 stood at $210.1 million (down 22.56% YoY), while the FY2025 annual figure was $241.0 million, down 15.41% from the prior year.
• Assets Average for Q1 2026 stood at $210.1 million, up from $201.5 million in the prior quarter.
• The five-year high for Assets Average was $504.0 million in Q1 2022, with the low at $201.5 million in Q4 2025.
• The 5-year median for Assets Average is $299.7 million (2023), against an average of $325.3 million.
• The sharpest annual moves came in 2022 and 2025: Assets Average soared 125.76% in 2022, then slumped 32.3% in 2025.
• Foghorn Therapeutics' Assets Average stood at $419.4 million in 2022, then retreated by 28.55% to $299.7 million in 2023, then fell by 1.17% to $296.2 million in 2024, then sank by 31.96% to $201.5 million in 2025, then climbed by 4.27% to $210.1 million in 2026.
• Business Quant data shows FHTX's Assets Average at $210.1 million in Q1 2026, $201.5 million in Q4 2025, and $215.6 million in Q3 2025.